Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other EventsItem 8.01.Other Events.
On February26, 2018, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing topline clinical trial results from a Phase 1 pharmacokinetic study of AXS-09, a novel, oral medicine consisting of chirally pure esbupropion and dextromethorphan being developed for the treatment of central nervous system disorders.
The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.
Item 8.01.Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description |
99.1 |
Press release dated February26, 2018. |